Concurrent Local Delivery of Diflunisal Limits Bone Destruction but Fails To Improve Systemic Vancomycin Efficacy during Staphylococcus aureus Osteomyelitis
- 23 June 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (7)
Abstract
Staphylococcus aureus osteomyelitis is a debilitating infection of bone. Treatment of osteomyelitis is impaired by the propensity of invading bacteria to induce pathologic bone remodeling that may limit antibiotic penetration to the infectious focus. The nonsteroidal anti-inflammatory drug diflunisal was previously identified as an osteoprotective adjunctive therapy for osteomyelitis, based on the ability of this compound to inhibit S. aureus quorum sensing and subsequent quorum-dependent toxin production. When delivered locally during experimental osteomyelitis, diflunisal significantly limits bone destruction without affecting bacterial burdens. However, because diflunisal9s “quorum-quenching” activity could theoretically increase antibiotic recalcitrance, it is critically important to evaluate this adjunctive therapy in the context of standard of care antibiotics. The objective of this study is to evaluate the efficacy of vancomycin to treat osteomyelitis during local diflunisal treatment. We first determined that systemic vancomycin effectively reduces bacterial burdens in a murine model of osteomyelitis, and identified a dosing regimen that decreases bacterial burdens without eradicating infection. Using this dosing scheme, we found that vancomycin activity is unaffected by the presence of diflunisal in vitro and in vivo. Similarly, locally-delivered diflunisal still potently inhibits osteoblast cytotoxicity in vitro and bone destruction in vivo in the presence of sub-therapeutic vancomycin. However, we also found that the resorbable polyurethane foams used to deliver diflunisal serve as a nidus for infection. Taken together, these data demonstrate that diflunisal does not significantly impact standard of care antibiotic therapy for S. aureus osteomyelitis, but also highlight potential pitfalls encountered with local drug delivery.Keywords
Funding Information
- HHS | National Institutes of Health (R01AR064772)
- HHS | National Institutes of Health (R01AI132560, K08AI113107)
- HHS | National Institutes of Health (T32GM007347, F30AI138424)
- Burroughs Wellcome Fund
This publication has 43 references indexed in Scilit:
- Detection of Staphylococcus aureus Delta-Toxin Production by Whole-Cell MALDI-TOF Mass SpectrometryPLOS ONE, 2012
- Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fracturesExpert Opinion on Drug Delivery, 2011
- Dual-Purpose Bone Grafts Improve Healing and Reduce InfectionJournal of Orthopaedic Trauma, 2011
- Identification of Genes Involved in Polysaccharide-Independent Staphylococcus aureus Biofilm FormationPLOS ONE, 2010
- Local Delivery of Tobramycin from Injectable Biodegradable Polyurethane ScaffoldsJournal of Biomaterials Science, Polymer Edition, 2010
- Trends in the Incidence of Methicillin‐ResistantStaphylococcus aureusInfection in Children’s Hospitals in the United StatesClinical Infectious Diseases, 2009
- The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional woundsBiomaterials, 2009
- Interconnections between Sigma B, agr , and Proteolytic Activity in Staphylococcus aureus Biofilm MaturationInfection and Immunity, 2009
- Bacterial quorum sensing: a new target for anti-infective immunotherapyExpert Opinion on Biological Therapy, 2008
- agr-Mediated Dispersal of Staphylococcus aureus BiofilmsPLOS Pathogens, 2008